Leal T, et al. Identifying resistance to immune checkpoint inhibitors by screening for PD-L1 and MHC I expression on CTCS in pts with NSCLC. IASLC 2018; abstract P3.04-08.
Sintilimab plus bevacizumab-biosimilar en chemotherapie voor EGFR-gemuteerd NSCLC met progressie na EGFR-TKI
nov 2022 | Longoncologie